Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of May 21, 2026, ACAD trades at $20.95 with a market cap of $3.54B and a P/E ratio of 9.34. ACAD moved +2.25% today. Year to date, ACAD is -19.89%; over the trailing twelve months it is -3.41%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is strong buy with an average price target of $32.77. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ACAD news today?
Acadia Q1 EPS $0.02, $268.1M Revenue Miss, $1.22B–$1.28B Outlook: Acadia posted Q1 net income of $3.6 million (2 cents EPS) on revenue of $268.1 million, missing analyst forecasts of 4 cents and $282.2 million. The company maintained full-year revenue guidance of $1.22–$1.28 billion as shares slip 19% YTD after a 49% one-year gain.
Acadia Q1 EPS $0.02, $268.1M Revenue Miss, $1.22B–$1.28B Outlook: Acadia posted Q1 net income of $3.6 million (2 cents EPS) on revenue of $268.1 million, missing analyst forecasts of 4 cents and $282.2 million. The company maintained full-year revenue guidance of $1.22–$1.28 billion as shares slip 19% YTD after a 49% one-year gain.
Does Rallies summarize ACAD news?
Yes. Rallies summarizes ACAD news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ACAD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACAD. It does not provide personalized investment advice.
